BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Faulding Pharmaceutical Co. And Faulding Puerto Rico, Inc. Announces Change Of Its Corporate Names To Mayne Pharma (USA) Inc. And Mayne Pharma (Pr) Inc.


10/19/2005 5:09:18 PM

PARAMUS, N.J., Dec. 1 /PRNewswire-FirstCall/ -- On December 1st, Faulding Pharmaceutical Co. and Faulding Puerto Rico, Inc. will change their business names to Mayne Pharma (USA) Inc. and Mayne Pharma (PR) Inc. respectively. These name changes are part of the global branding strategy of its parent company, Mayne Group Limited.

Mayne's global capabilities stretch from production of Active Pharmaceutical Ingredient (API) to the manufacture of over 120 molecules for distribution in 50 countries.

In making the announcement, Stuart Hinchen, the president of Mayne Pharma in the Americas, said: "Our new corporate name is being adopted at an exciting time for our company. The acquisition of Faulding by Mayne in 2001 laid the foundation for an aggressive corporate development program involving both organic growth and strategic acquisitions. This corporate growth is strengthening our standing as a leading pharmaceutical company in the United States".

"Our growth strategy is focused on one key goal: bolstering our ability to deliver quality, cost-effective products and services to hospitals nationwide," Mr. Hinchen added.

Mayne Pharma will continue to focus on expanding their offering of hospital injectable products in defined therapeutic areas. These include oncology, anesthesia/pain, anti-infectives, as well as drugs for the treatment of cardiac conditions and to combat hypertension.

The purchases of the North American Paclitaxel rights from Abbott Laboratories in September, and Methotrexate and Leucovorin from Xanodyne Pharmacal, Inc. in October demonstrate their commitment to growth. In December they anticipate to complete the acquisition of the worldwide Paclitaxel API manufacturing business from NaPro BioTherapeutics, Inc.

Mayne's launches of Hydromorphone and Pamidronate, combined with the imminent launches of Fluconazole and Carboplatin highlight their strong development capabilities and focus on meeting the needs of our customers.

Mr. Hinchen added, "As Mayne Pharma grows and diversifies we remain committed to providing comprehensive after-sales service to our customers, and to promoting fairness in our relationships with business partners."

Mayne Pharma (USA) Inc. is a subsidiary of Mayne Group Limited, which is listed on the Australian Stock Exchange. Mayne has core businesses in pharmaceuticals (the manufacture of injectable and oral pharmaceuticals for distribution to more than 50 countries), health services (pathology, diagnostic imaging, medical centers, and pharmacy services), and health-related consumer products.

Mayne Group Limited

CONTACT: Joe Marchese, VP Sales and Marketing of Mayne Group Limited,+1-201-225-5531



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES